Pantoprazol Tillomed (Pantoprazole)

Pantoprazole selectively and irreversibly inhibits the gastric H+/K+ ATPase (proton pump) in parietal cells, blocking the final step of acid secretion. This leads to a sustained increase in gastric pH and a reduction of both basal and stimulated gastric acid output.

The dosage and infusion rate are determined by the prescribing clinician based on the specific indication, disease severity, and patient characteristics. The prescriber sets the appropriate dose and duration according to clinical guidelines.

The safety of pantoprazole during pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under the guidance of a qualified healthcare professional.

To request Pantoprazol Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Pantoprazole belongs to the proton pump inhibitor class, offering more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, it has a low potential for drug‑drug interactions and is available in an injectable formulation for rapid onset in hospital settings.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations.

Pantoprazol Tillomed is given by intravenous infusion, typically diluted in compatible IV fluids and administered over a short period as directed by the treating physician. Administration is performed in a clinical setting with appropriate monitoring.

Serious adverse reactions can include severe allergic responses such as anaphylaxis, Clostridioides difficile‑associated diarrhea, acute interstitial nephritis, hepatic dysfunction, thrombocytopenia, and significant electrolyte disturbances like hypomagnesemia. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to pantoprazole or other proton pump inhibitors should avoid the product. Caution is advised in individuals with severe hepatic impairment, those receiving drugs that require an acidic gastric environment, and in patients where the benefit does not outweigh potential risks, as determined by a healthcare professional.